Management of Sjögren's Syndrome

Management of Sicca Symptoms

The American College of Rheumatology recommends first-line therapy with artificial tears containing methylcellulose or hyaluronate at least twice daily for ocular dryness, with frequency increased based on symptoms 1
Preservative-free formulations should be used for patients requiring four or more applications of artificial tears per day 1
Ophthalmic ointments can be used before bedtime for overnight symptom control of ocular dryness 1
For refractory or severe ocular dryness, topical cyclosporine A is recommended for patients who don't respond to artificial tears 1
Autologous serum eye drops may be considered for persistent symptoms of ocular dryness 2
Non-pharmacological management includes sugar-free gum and frequent sips of water for mild salivary gland dysfunction 2
For moderate salivary gland dysfunction, pharmacological stimulation with muscarinic agonists is recommended 1, 2
Saliva substitution products are recommended for severe salivary gland dysfunction with no salivary output 2

Approximately 38% of Sjögren's patients have chronic cough, which requires evaluation if persisting >8 weeks 3, 4, 5
Assessment should begin with common causes (asthma, GERD, upper airway cough syndrome) before evaluating for Sjögren's-specific complications 3
For xerotrachea (dry trachea), empirical humidification and trial of secretagogue and/or guaifenesin is recommended 3, 5
Asthma/COPD should be managed with inhaled corticosteroids and beta-agonists, avoiding anticholinergics to prevent further drying of secretions 3, 4, 5
Bronchiolitis may be treated with a short course of empiric macrolide antibiotics (azithromycin 250 mg 3 days/week) for persistent, symptomatic bronchiolitis 5, 6
Bronchiectasis should be treated with multiple approaches, including mucolytic agents/expectorants, nebulized saline or hypertonic saline, oscillatory positive expiratory pressure, postural drainage, and mechanical high-frequency chest wall oscillation therapies 3, 5, 6

Evaluate for contributing conditions and use analgesics according to pain severity following the WHO pain ladder for fatigue and pain management 1, 2
Hydroxychloroquine may be considered for fatigue and arthralgias, though evidence for efficacy is limited 1
For chronic, non-inflammatory pain, physical activity and aerobic exercise are recommended rather than medications 1, 7
Short-term moderate-dose glucocorticoids may be considered for acute pain 2

Systemic therapies should be restricted to patients with active systemic disease, with treatment tailored to organ-specific severity using the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) 1, 7
For moderate to severe systemic disease, glucocorticoids at minimum effective dose and duration, and immunosuppressive agents (azathioprine, mycophenolate, methotrexate) as glucocorticoid-sparing agents are recommended 1, 2, 7
For refractory disease, B-cell targeted therapies, particularly rituximab, may be considered 2, 7
First-line treatment for interstitial lung disease is systemic corticosteroids, with first-line maintenance using mycophenolate mofetil or azathioprine, and antifibrotic therapy with nintedanib as second-line maintenance for progressive fibrotic interstitial lung disease 2

Regular assessment of disease activity using validated tools such as the ESSDAI is recommended 1, 7
For patients with pulmonary involvement, repeat pulmonary function tests every 6-12 months 1
Monitor for development of lymphoma, which occurs in 2-5% of Sjögren's patients 1, 7
A reduction of ≥3 points in the global ESSDAI score is considered a therapeutic response in systemic Sjögren's syndrome 7